Generated by DeepSeek V3.2| Louis Picker | |
|---|---|
| Name | Louis Picker |
| Nationality | American |
| Fields | Immunology, Virology, Vaccine development |
| Workplaces | Oregon Health & Science University, Oregon National Primate Research Center |
| Alma mater | University of California, San Diego, University of Miami |
| Known for | Cytomegalovirus-based HIV vaccine research |
| Awards | NIH Director's Pioneer Award, Robert M. Chanock Award |
Louis Picker is an American immunologist and virologist renowned for his pioneering work in T cell immunology and novel vaccine design, particularly his development of a cytomegalovirus (CMV)-vectored vaccine strategy aimed at eliciting durable, effective T cell responses against challenging pathogens. His research, primarily conducted at the Oregon Health & Science University (OHSU) and the affiliated Oregon National Primate Research Center, has focused on understanding immune memory and applying these principles to create vaccines for diseases like HIV/AIDS and tuberculosis. Picker's innovative approach has positioned him as a leading figure in the quest for a functional cure for HIV.
Picker completed his undergraduate studies at the University of California, San Diego, where he developed an early interest in biological sciences. He then pursued his medical degree at the University of Miami Leonard M. Miller School of Medicine, graduating with an M.D. His clinical and scientific training provided a strong foundation in human pathology and infectious disease, which later informed his research direction. Following medical school, he engaged in postdoctoral training focused on immunology, solidifying his expertise in the mechanisms of the adaptive immune system.
Picker's academic career has been centered at Oregon Health & Science University, where he is a professor in the Vaccine and Gene Therapy Institute and serves as the associate director of the Oregon National Primate Research Center. His early research made significant contributions to the understanding of lymphocyte trafficking, particularly the role of adhesion molecules and chemokine receptors in guiding T cell migration to tissues. This work provided critical insights into how the immune system surveys the body for pathogens. His laboratory has extensively utilized the rhesus macaque model of SIV infection to study HIV pathogenesis and immunity, establishing key correlates of immune protection.
Picker's most notable scientific contribution is the development of a novel vaccine platform using a genetically modified strain of cytomegalovirus (CMV) as a vector. Unlike conventional vaccines that aim to prevent infection, Picker's CMV vector is engineered to persistently stimulate effector memory T cells in tissues, creating a state of constant immune surveillance. In landmark studies published in journals like Nature and Science, his team demonstrated that vaccination with this SIV-specific CMV vector could control and eventually clear established SIV infection in a significant proportion of rhesus macaques, an unprecedented result in the field. This research, supported by the National Institutes of Health and the Bill & Melinda Gates Foundation, suggests the potential for a therapeutic vaccine that could functionally cure HIV without lifelong antiretroviral therapy.
In recognition of his innovative research, Picker has received several prestigious awards. He is a recipient of the NIH Director's Pioneer Award, a grant supporting highly creative scientists with bold approaches to major challenges in biomedical research. His contributions to virology and immunology were further honored with the Robert M. Chanock Award for Lifetime Achievement in Respiratory Virus Research from the National Institute of Allergy and Infectious Diseases. His work has also been recognized through invitations to speak at major international conferences, including the International AIDS Conference and the Keystone Symposia.
Picker maintains a relatively private personal life, with public information focusing primarily on his professional achievements. He is known within the scientific community for his collaborative approach and mentorship of trainees at Oregon Health & Science University. His dedication to translating basic immunological discoveries into practical interventions for global health threats like HIV/AIDS and tuberculosis continues to drive his research program.
Category:American immunologists Category:American virologists Category:HIV/AIDS researchers Category:Oregon Health & Science University faculty Category:University of California, San Diego alumni Category:University of Miami alumni